SIGA Technologies — Strong order book moving into Q424

SIGA Technologies (NASDAQ: SIGA)

Last close As at 03/12/2024

USD6.64

−0.51 (−7.13%)

Market capitalisation

USD474m

More on this equity

Research: Healthcare

SIGA Technologies — Strong order book moving into Q424

SIGA Technologies reported revenues of $10m in Q324, attributed primarily to deliveries under the $112.5m BARDA option, exercised in July 2024. Backed by a strong order book ($146m at end-Q324), the sales momentum has picked up pace in Q424 with another $51.2m and $8.5m of oral and IV TPOXX (IVT) delivered to the Strategic National Stockpile (SNS) in October 2024. We expect further deliveries in Q424 and early 2025 under the BARDA contract as well as the $9m US Department of Defense (DoD) order received in August 2024. Q424 also marked SIGA’s first commercial foray into Africa (delivering oral TPOXX to Morocco worth c $0.8m), capped by in-licensing of a novel preclinical monoclonal antibody from Vanderbilt University to complement TPOXX in targeting orthopox viruses. We await further updates on the PEP label expansion and mpox trials but conservatively adjust our estimates to reflect results from the PALM 007 study. Our valuation adjusts to $13.93/share from $15.89/share previously.

Jyoti Prakash

Written by

Jyoti Prakash

Analyst, Healthcare

Healthcare

SIGA Technologies

Strong order book moving into Q424

Q324 results

Pharma and biotech

18 November 2024

Price

$5.94

Market cap

$424m

Net cash ($m) at 30 September 2024

99.3

Shares in issue

71.4m

Free float

56%

Code

SIGA

Primary exchange

Nasdaq

Secondary exchange

N/A

Share price performance

%

1m

3m

12m

Abs

(11.9)

(38.3)

16.2

Rel (local)

(12.7)

(41.7)

(10.8)

52-week high/low

$11.97

$4.51

Business description

SIGA Technologies is a commercial-stage pharmaceutical company focused on the treatment of smallpox and other infectious diseases. It has partnerships with governments and public health agencies in the US, Canada and Europe for TPOXX, its treatment for smallpox, and is expanding internationally.

Next events

BARDA and US DoD oral TPOXX deliveries

Q424

FY24 results

March 2025

Analysts

Jyoti Prakash, CFA

+44 (0)20 3077 5700

Dr Arron Aatkar

+44 (0)20 3077 5700

SIGA Technologies is a research client of Edison Investment Research Limited

SIGA Technologies reported revenues of $10m in Q324, attributed primarily to deliveries under the $112.5m BARDA option, exercised in July 2024. Backed by a strong order book ($146m at end-Q324), the sales momentum has picked up pace in Q424 with another $51.2m and $8.5m of oral and IV TPOXX (IVT) delivered to the Strategic National Stockpile (SNS) in October 2024. We expect further deliveries in Q424 and early 2025 under the BARDA contract as well as the $9m US Department of Defense (DoD) order received in August 2024. Q424 also marked SIGA’s first commercial foray into Africa (delivering oral TPOXX to Morocco worth c $0.8m), capped by in-licensing of a novel preclinical monoclonal antibody from Vanderbilt University to complement TPOXX in targeting orthopox viruses. We await further updates on the PEP label expansion and mpox trials but conservatively adjust our estimates to reflect results from the PALM 007 study. Our valuation adjusts to $13.93/share from $15.89/share previously.

Year end

Revenue
(US$m)

EBITDA*
(US$m)

PBT*
(US$m)

EPS*
(US$)

P/E
(x)

Yield

(%)

12/22

110.8

43.2

43.7

0.46

12.9

7.6

12/23

139.9

84.2

87.8

0.95

6.2

10.1

12/24e

160.2

90.0

96.1

1.05

5.7

11.8

12/25e

184.4

110.2

116.1

1.26

4.7

12.6

Note: *EBITDA, PBT and EPS (basic) are normalized, excluding amortization of acquired intangibles, exceptional items and share-based payments.

BARDA oral TPOXX deliveries initiated in Q324

SIGA delivered $8.1m worth of oral TPOXX to the SNS in Q324 with another $51.2m of oral TPOXX and $8.5m of IVT (which we believe completes the August 2022 order) delivered in October 2024. We model a further $30m to be serviced in Q424 (adding up to c 80% of the oral TPOXX order book). We remind readers that this was the last order under the 2018 BARDA contract and SIGA is preparing for a request for proposal (RFP) from the US government for a potentially long-term, higher-value contract. Given the BARDA mandate of stockpiling two smallpox treatments in the SNS, we see material likelihood of a contract win for SIGA in the near term. We also expect the $25m July 2023 IVT order to be delivered in 2025.

Mpox opportunity still in play?

Notwithstanding the slight setback from the PALM 007 trial (which missed the primary endpoint), SIGA sees merit in continuing to test the mpox opportunity in other ongoing trials, given the efficacy signals in subsets of patients in the PALM study. We await data from the US-based STOMP trial, which is expected to read out in the near term, but conservatively introduce a 50% sensitivity factor to our estimates for the mpox opportunity, to account for the increased risk.

Valuation: Adjusts to $13.93/share

We make minor adjustments to our estimates to reflect the 9M24 performance and cash position. The more significant change to our valuations comes from the aforementioned risk-adjustment to the mpox estimates, which results in our valuation adjusting to $1.0bn or $13.93/share (from $1.13bn or $15.89/share).

Strong order book provides near-term revenue visibility

Q324 top line reflects TPOXX deliveries under the BARDA order

Q324 was a strong quarter for SIGA in terms of its order book, with the company receiving $122m in new TPOXX orders during the period. This includes the $112.5m order received in July under the 19c BARDA contract as well the $9m order from the US DoD for oral TPOXX, and a small amount of IV TPOXX, received in August 2024. Of the BARDA contract, $8.1m was delivered within Q324, making up the bulk of the $8.9m in product revenues recorded in the quarter. The remaining $0.8m was attributable to international sales of oral TPOXX, which we believe was related to delivery of oral TPOXX to the Ministry of Health in Morocco. In contrast, in Q323 SIGA had reported product sales of $8m, attributable to international orders. We highlight that due to SIGA’s business model (deliveries based on government contracts and orders) revenues can be lumpy, and therefore period-on-period comparisons are often difficult. R&D-related revenues amounted to $1.1m ($1.3m in Q323) and comprised activities under the 19C BARDA contract. Note that the R&D-related revenue figures have stayed in this range since Q323, following the conclusion of the $27m BARDA funding for the PEP label expansion program during the period.

R&D expenses were in line with the previous two quarters ($3.0m versus $2.9m and $3.0m in Q224 and Q124, respectively) following decreased R&D activity related to the PEP label expansion program, given the ongoing sample re-analysis by the Centers for Disease Control and Prevention (CDC) (discussed in more detail later in this report). On the other hand, SG&A expenses saw a significant decline due to lower promotion fees paid to distribution partner Meridian, given the decrease in international sales. This was partially offset by higher executive compensation. We note that while Meriden was previously entitled to receive 20% of sales proceeds as fees, the agreement was amended in March 2024 (and effective in June 2024), with SIGA taking primary responsibility for marketing and promotion. Under the revised agreement, Merdian will now be entitled to a fee equal to a high single-digit percentage of collected proceeds from territories specified in the revised contract. Overall, operating and net profit for the quarter were $0.5m and $1.3m, respectively, versus an operating and net loss of $1.3m and $0.4m in Q323.

Slight estimate revisions based on Q324 results

SIGA ended Q324 with a strong order book, worth $146m, which we understand included $104m of pending deliveries of oral TPOXX and c $8m of IVT (under the August 2022 order) to BARDA, $25m in IVT deliveries under the July 2023 order from BARDA and $9m of TPOXX orders by the DoD, received in August 2024. Of this, $51.2m of oral TPOXX and $8.5m of IVT (we believe this completes deliveries under the August 2022 order) were delivered in October 2024. We continue to expect 80% of the $112.5m order to be delivered within 2024, and therefore model another $30m of oral TPOXX deliveries in Q424. We also keep our estimate of deliveries under the $25m IVT order (July 2023) unchanged to 2025. Management has highlighted that the manufacturing process of IVT is more complex than that of oral TPOXX and uses certain different raw materials, which require longer manufacturing lead times, to oral TPOXX. We believe this accounts for the more protracted delivery of IVT versus oral TPOXX.

We also adjust our FY24 revenue projections for the $9m order received from the DoD in August 2024, estimating it to be fully serviced within Q424. The upside from this inclusion has been partially offset by adjustments we have made to our previous assumptions of deliveries to Canada. We note that SIGA holds a $6.7m contract with the Canada Department of National Defence, which the authority can exercise by 31 December 2025. We had previously assumed $3m to be delivered in 2024 and $3.7m in 2025 but now expect the entire order in 2025. We were also assuming a $3.5m order from the Public Health Agency of Canada, which we have now removed. Overall, we
expect FY24 and FY25 revenues to be $160.2m and $184.4m, respectively, versus $160.4m and $186.9m previously.

We have also adjusted our FY24 SG&A estimate ($24.9m vs $29.6m previously) to reflect the first nine months of 2024 (9M24) performance, while keeping our R&D and COGS assumptions broadly unchanged. Overall, we expect FY24 and FY25 operating profit to be $89.4m and $109.6m, respectively, versus $85.7m and $109.2m previously.

Several moving parts to underpin future growth

While the end-Q324 order book secures revenues for Q424 and into 2025, management highlighted the company’s continued focus on optimizing long-term value of its orthopox therapeutics franchise through various strategic initiatives. We discuss these in more detail below.

Targeting a new BARDA contract in 2025

As noted previously, the latest $112.5m BARDA option exercise was the last for oral TPOXX under the 19C BARDA contract, which had a $546m procurement value. There is one pending option for IVT, worth $26.5m, and we expect it to be exercised in 2025, with deliveries in 2026. Management has communicated that it is in discussions with the relevant US authorities and is preparing for an RFP from the US government for a new, higher-value and potentially long-term (up to 10 years) contract. Management expects the new contract to be signed in 2025, including delivery of an initial order under the contract terms.

We highlight that SIGA has a longstanding relationship with the US government authorities and TPOXX has been stockpiled under the SNS since 2011. Moreover, the research and development activities for TPOXX were co-funded by BARDA, and the PEP program was funded by the US DoD. We note that the Administration for Strategic Preparedness and Response (ASPR), of which BARDA is a part, mandates stockpiling of two separate smallpox antiviral treatments. TPOXX is one of only two smallpox treatments currently approved by the FDA, with a strong safety profile (the other treatment is Tembexa, which comes with a black box warning). Given this, and the US government’s continued commitment to preparedness against biothreats, we see a high likelihood of SIGA securing a new contract in 2025. Our model assumes annual oral TPOXX deliveries in 2025 to be similar to those under the 2018 contract, but we note that this is subject to modification as per the timing and value of the new contract.

Regulatory filing under the PEP label expected in Q325

SIGA’s PEP label expansion program positions TPOXX as a prophylaxis treatment for individuals at high risk of exposure. While antiviral treatments are traditionally administered after symptoms appear, prophylaxis treatment requires the administration of the drug following exposure and before symptoms appear. This entails a 28-day regimen, versus 14 days in the treatment indication of TPOXX, and therefore holds the potential to significantly increase the market opportunity for SIGA. We remind readers that while all clinical trial-related activities have been completed (the expanded safety study did not indicate any drug-related serious adverse events), samples from the immunogenicity trial (testing TPOXX plus JYNNEOS, an FDA-approved smallpox vaccine) are being retested by the CDC after the trial indicated the measurable immune response to the JYNNEOS vaccine in both groups was lower than expected. Management has communicated that the CDC re-analysis is expected to complete in H125, and SIGA now plans to file a supplementary new drug application (NDA) in Q325. Our model currently assumes a 2026 launch under the PEP label.


Trial activity ongoing to test the mpox opportunity

While TPOXX is approved in the EU and UK for all orthopoxviruses (including mpox), US approval requires SIGA to conduct in-human studies. Management is supporting several randomized controlled clinical trials (funded by government entities) evaluating TPOXX as a treatment for mpox and recruitment is ongoing across four separate trials – STOMP (US and South America), UNITY (Argentina, Brazil, Switzerland), PLATINUM-CAN (Canada) and EPOXI (Europe). In August 2024, SIGA reported top-line results from the PALM 007 trial (studying TPOXX as a treatment of mpox in the Democratic Republic of the Congo), sponsored by the National Institute of Allergy and Infectious Diseases (NIAID). While the study did not meet statistical significance on its primary endpoint of improvement in lesions versus placebo within 28 days post-randomization, SIGA noted significant improvement in a subset of patients – those whose symptoms began up to seven days prior to randomization, and in those with severe disease (≥100 lesions). SIGA and NIAID are pursuing a detailed analysis of the results.

We note that the PALM 007 study was not a registration trial, and SIGA’s priorities in mpox are the four remaining ongoing studies targeting this indication. We believe that results from the STOMP trial, in particular, will be of importance, given that it is the largest ongoing trial and is US-focused. According to the latest update by management, the study had enrolled a total of 670 patients as of the first week of October, up from 515 at the time of the previous update call. We expect top-line results from the trial in H125.

Mpox is caused by two virus strains, Clade I and Clade II, which have further divided into subclades – Clade Ia, Clade Ib and Clade IIa. According to the CDC, Clade IIb, which spread globally in 2022, has resulted in over 100,000 cases of mpox in 122 countries. More recently, the emergence of a more serious strain, Clade I, in the Democratic Republic of the Congo (5% death rate versus 0.2% with Clade II) is worrisome, although the spread is currently limited to neighboring African countries. According to the CDC, since January 2024, a total of 15,994 mpox cases have been reported globally, indicating that mpox continues to be of concern. Management has noted that over 8,000 patients were administered TPOXX under compassionate use during the height of the outbreak and a further 2,000 patients have participated in the TPOXX randomized trials.

Continued expansion of global footprint

International expansion continues to be one of the key priorities for SIGA and the company has significantly expanded its international presence in the past couple of years (over 25 countries now). During Q324, SIGA made its first commercial entry into Africa (currently only available under emergency use protocols) following recent inroads across Europe and Asia-Pacific. In September 2024, the company signed an agreement with the Ministry of Health in Morocco to supply its antiviral treatment TPOXX, recording proceeds of $0.8m in the quarter. We note that this was also the first international agreement undertaken independently by SIGA, without distribution partner Meridian, following the amended agreement, as detailed above. Management also provided an update on the NDA filing (in April 2024) by SIGA’s partner, Japan Biotechno Pharma (for oral TPOXX under the broad orthopox label), for which a regulatory decision is expected in early 2025.

Portfolio expansion with new licensing agreement

In October 2024, SIGA in-licensed a new preclinical portfolio of monoclonal antibodies (mAb) from the Vanderbilt University Medical Center for an undisclosed consideration. This will be developed as a potential treatment as well as a prophylactic consideration for a range of orthopoxviruses and we expect it to complement the company’s approved antiviral treatment, TPOXX. The mAb program has reported encouraging preclinical data and has secured funding from the US DoD to advance R&D efforts through Phase I clinical development. SIGA plans to develop the program as either a monotherapy or in combination with TPOXX.

Monoclonal antibodies are considered to be a promising treatment option for smallpox, as they work by binding to specific proteins on the variola virus (which causes smallpox) to neutralize it and decrease the viral load in the body for the immune system to fight. One such treatment is under development by BioFactura (Phase I trial is expected to start in H225) with R&D backing from the BARDA.

Valuation

We value SIGA using the standard risk-adjusted net present value (rNPV) approach, forecasting each of its programs to the end of the patent life in each geography. We make certain minor adjustments to our near-term estimates based on the Q324 results but keep our long-term assumptions broadly unchanged for now. The key change to our valuation comes from the risk sensitivity (50%) we introduce to our mpox projections, to reflect the results from the PALM 007 study. We also assume the approval under the mpox label to come in 2026 versus 2025 previously. These changes, along with the latest net cash figure ($99.3m, the company remains debt free) result in our valuation for SIGA adjusting to $1.0bn or $13.93/share, from $1.13bn or $15.89/share. Exhibit 1 presents a breakdown of our rNPV valuation.

Exhibit 1: rNPV valuation of SIGA

Product/program

Main indication

Status

Probability of success

Approval/launch/
first contract year

Peak sales ($m)

rNPV
($m)

TPOXX (US base – Oral)

Treatment of smallpox

On market

100%

2018

122

319

TPOXX (Canada)

Treatment of smallpox

On market

100%

2020

13

31

TPOXX US IV and pediatric formulations

Treatment of smallpox

IV (NDA approved May 2022), pediatric (being formulated)

50–100%

2022–26

30

31

TPOXX US PEP

Post-exposure prophylaxis following exposure to smallpox

Development

50%

2026

121

211

TPOXX EU, Japan, Korea, Australia

Treatment of smallpox

EMA approved

55%

2022

279

234

Commercialization of TPOXX, PEP in US, Canada, Europe, Asia

Treatment of mpox

Development

50%

2026

52

71

Total

 

 

 

 

896

Net cash (Q324) ($m)

99.3

Total firm value ($m)

995

Total basic shares (m) outstanding

71.4

Value per basic share ($)

$13.93

Source: Edison Investment Research

Exhibit 2: Financial summary

$000s

2022

2023

2024e

2025e

Year end 31 December

US GAAP

US GAAP

US GAAP

US GAAP

PROFIT & LOSS

 

 

 

Revenue

 

 

110,776

139,917

160,209

184,362

Of which Product revenue

86,662

130,668

155,585

178,813

Of which R&D revenue

24,114

9,249

4,625

5,549

Cost of Sales

(10,433)

(17,825)

(33,666)

(30,704)

Gross Profit on product sales

76,229

112,843

121,919

148,109

Research & Development

(22,526)

(16,428)

(12,321)

(13,553)

General & Administrative

(35,117)

(22,043)

(24,853)

(30,480)

EBITDA

 

 

43,218

84,159

89,961

110,217

Operating profit (before amort. and excepts.)

 

 

42,700

83,621

89,369

109,624

Net Interest

1,032

4,156

6,757

6,481

Exceptionals

401

-

-

-

Profit Before Tax (norm)

 

 

43,732

87,777

96,125

116,106

Profit Before Tax (reported)

 

 

44,133

87,777

96,125

116,106

Tax

(10,228)

(19,708)

(21,582)

(26,068)

Deferred tax

-

-

-

-

Profit After Tax (norm)

33,504

68,069

74,543

90,037

Profit After Tax (reported)

33,905

68,069

74,543

90,037

Average Number of Shares Outstanding (m)

73

71

71

71

EPS - normalized ($), basic

 

 

0.46

0.95

1.05

1.26

EPS - normalised fully diluted ($)

 

 

0.46

0.95

1.04

1.25

EPS - reported ($)

 

 

0.46

0.95

1.05

1.26

 

 

 

Gross Margin (%)

88

86

78

83

EBITDA Margin (%)

39

60

56

60

Operating Margin (before GW and except.) (%)

39

60

56

59

 

 

 

BALANCE SHEET

 

 

 

Fixed Assets

 

 

9,250

15,362

14,791

14,221

Intangible Assets

898

898

898

898

Tangible Assets

1,848

1,332

761

191

Other

6,503

13,132

13,132

13,132

Current Assets

 

 

185,786

238,991

252,646

295,583

Stocks

39,273

64,218

67,429

70,801

Debtors

45,407

21,131

19,018

20,920

Cash

98,791

150,146

162,036

199,078

Other

2,316

3,496

4,163

4,784

Current Liabilities

 

 

(21,518)

(54,118)

(33,280)

(33,540)

Creditors

(3,355)

(1,456)

(1,407)

(1,667)

Short term borrowings

-

-

-

-

Other

(18,162)

(52,661)

(31,873)

(31,873)

Long Term Liabilities

 

 

(3,358)

(3,376)

(3,376)

(3,376)

Long term borrowings

-

-

-

-

Other long term liabilities

(3,358)

(3,376)

(3,376)

(3,376)

Net Assets

 

 

170,160

196,859

230,781

272,888

Minority Interests

-

-

-

-

Shareholder equity

 

 

170,160

196,859

230,781

272,888

 

 

 

CASH FLOW

 

 

 

Operating Cash Flow

 

 

41,611

94,799

54,585

87,047

Capex

-

(22)

(22)

(22)

Acquisitions/disposals

-

-

-

-

Financing

-

-

-

-

Dividends

(32,940)

(32,135)

(42,674)

(49,983)

Other (including share buybacks)

(13,019)

(11,287)

-

-

Net Cash Flow

(4,348)

51,355

11,890

37,042

Opening net debt/(cash)

 

 

(103,139)

(98,791)

(150,146)

(162,036)

Exchange rate movements

-

-

-

-

Other

-

-

-

-

Closing net debt/(cash)

 

 

(98,791)

(150,146)

(162,036)

(199,078)

Source: Company reports, Edison Investment Research


General disclaimer and copyright

This report has been commissioned by SIGA Technologies and prepared and issued by Edison, in consideration of a fee payable by SIGA Technologies. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright: Copyright 2024 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

London │ New York │ Frankfurt

20 Red Lion Street

London, WC1R 4PS

United Kingdom

London │ New York │ Frankfurt

20 Red Lion Street

London, WC1R 4PS

United Kingdom

General disclaimer and copyright

This report has been commissioned by SIGA Technologies and prepared and issued by Edison, in consideration of a fee payable by SIGA Technologies. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright: Copyright 2024 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

London │ New York │ Frankfurt

20 Red Lion Street

London, WC1R 4PS

United Kingdom

London │ New York │ Frankfurt

20 Red Lion Street

London, WC1R 4PS

United Kingdom

More on SIGA Technologies

View All

Latest from the Healthcare sector

View All Healthcare content

Research: Metals & Mining

The Metals Company — Updated strategy offers commercial upside

Progress to an exploitation licence and commercialisation of The Metals Company’s (TMC’s) deep-sea assets is unchanged. The development of a strategy to leverage the group’s knowledge and capabilities in the deep sea to provide services to third parties offers the potential of a new and earlier revenue stream.

Continue Reading

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free